Taken together, these findings imply that combined inhibition of BTK and IDH1 along with IMiDs can be regarded as effective treatment strategies to enhance the efficacy against hematological cancer cells and offer an alternative way to tackle acquired resistance. This evidence concerns the gene BTK and hematopoietic and lymphoid cell neoplasm.